Case Studies

2024-11-04

Recombinant Antibody Expression & Functional QC Validation | AtaGenix

AtaGenix's recombinant antibody expression pipeline delivers assay-grade antibody from sequence to validated reagent. This case demonstrates the full QC workflow: SDS-PAGE (reducing + non-reducing) confirming correct HC/LC assembly and purity, SEC-HPLC verifying monomer content, endotoxin testing by LAL, and functional validation confirming antigen-specific binding. Every batch ships with dual verification — purity and function — ensuring the antibody works in the client's downstream application on the first attempt.

2024-11-04

SARS-CoV-2 Spike Protein: From Sequence to Assay-Grade Antigen in 18 Days | AtaGenix

A diagnostics partner needed assay-grade SARS-CoV-2 spike protein with native glycosylation. AtaGenix delivered >95% purity trimeric protein via HEK293 transient expression in 18 days — achieving 3.5x ELISA signal improvement over E. coli-derived RBD and enabling rapid serological kit validation.

2024-10-21

XtenCHO™ High-Density Expression: 500–1,500 mg/L Antibody Yields in Transient Timelines | AtaGenix

AtaGenix's proprietary XtenCHO™ platform benchmarked across 11 therapeutic antibodies: median yields 500–1,000 mg/L, top performer ~1,500 mg/L, with near-100% CHO cell viability sustained over 15-day cultures. XtenCHO™ bridges the gap between standard transient expression (100–300 mg/L, 5–7 days) and stable cell lines (12+ weeks development) — delivering stable-line-level yields in transient timelines for preclinical material generation and multi-candidate parallel evaluation.